Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ EGFL7 Polyclonal Antibody
Goat Polyclonal Antibody
Supplier: Invitrogen™ PA5143248
This item is not returnable.
View return policy
Description
Additional Information: The immunizing peptide represents the N terminus of the mature protein. This antibody is tested in Peptide ELISA: antibody detection limit dilution 1:128,000.
Epidermal growth factor-like protein 7 (EGFL7), also known as VE-statin, MEGF7, Notch4-like protein or Zneu1, is a 29.6 kDa protein produced and secreted by endothelium. The protein is also expressed by some normal and malignant tissues. The main function of EGFL7 is to regulate angiogenesis and vasculogenesis. A high level of EFGL-7 can be found in tissues with active angiogenesis of a variety of disorders.
Specifications
EGFL7 | |
Polyclonal | |
Unconjugated | |
EGFL7 | |
Cbl20; EGF like domain multiple 7; EGFL7; EGF-like domain 7; EGF-like domain-containing protein 7; EGF-like protein 7; EGF-like-domain, multiple 7; Epidermal growth factor-like protein 7; Estrogen-regulated protein CBL20 20.4kD; Estrogen-regulated protein CBL20, 20.4kD; Megf7; multiple EGF-like domain protein 7; multiple EGF-like domains protein 7; multiple epidermal growth factor-like domain protein 7; multiple epidermal growth factor-like domains protein 7; NEU1; NEU1 protein; NOTCH4-like protein; RP11-251M1.2; UNQ187/PRO1449; Vascular endothelial statin; vascular endothelial-statin; VE-STATIN; Zneu1 | |
Goat | |
Ammonium sulfate precipitation | |
RUO | |
51162 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Western Blot | |
0.5 mg/mL | |
TBS with 0.5% BSA and 0.02% sodium azide; pH 7.3 | |
Q9UHF1 | |
EGFL7 | |
Peptide with sequence C-HGDPVSESFVQR. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction